Login here to update your profile  
My Profile

Andreas Seyfang, Ph.D.

Primary Department: COLLEGE OF MEDICINE MOLECULAR MEDICINE

Associate Professor, COLLEGE OF MEDICINE MOLECULAR MEDICINE

Associate Professor (joint appointment), School of Physical Therapy & Rehabilitation Sciences, College of Medicine

Associate Professor (joint appointment), Department of Internal Medicine- Division of Infectious Diseases, College of Medicine

Associate Professor (joint appointment), Department of Global Health, College of Public Health

Associate Professor (joint appointment), Department of Neurosurgery, College of Medicine

Associate Professor, Department of Molecular Medicine, College of Medicine

profile Image
Contacts
Email: aseyfang@health.usf.edu
Phone: (813) 974-2332
Office: MDC, 4022A
Mailing address Molecular Medicine, MDC Box 7 12901 Bruce B. Downs Blvd.
Tampa, FL 33612
View My C.V.
 
Education
  • Postdoc, Molecular Microbiology, Oregon Health Sciences University, USA - 1995.
  • Postdoc, Molecular Parasitology, University of Bordeaux, Bordeaux, France - 1993.
  • PHD, Biochemistry, University Of Tubingen, Tübingen, Germany - 1993.
  • MSc, Parasitology, Zoology, University of Tübingen, Tübingen, Germany - 1989.
  • DAAD Scholar, Microbiology, Parasitology, Duke University, USA - 1984.
  • BSc, Biology, University of Tübingen, Tübingen, Germany - 1983.
 
Interdisciplinary & Emerging Signature Programs
Allergy, Immunology & Infectious Disease, Cardiovascular, Neuroscience.
 
Research Summary

LABORATORY OF MEDICAL MICROBIOLOGY AND MOLECULAR PARASITOLOGY: Research in the Seyfang laboratory focuses on two major projects (i) membrane permeases (transporters) as target for drug delivery and (ii) cytochrome b5 reductase as enzymatic drug target in opportunistic microbial pathogens including protozoan parasites and nosocomial and neuro-pathogenic fungi. We are studying membrane permeases (transporters) and receptors in opportunistic microbial pathogens including protozoan parasites (trypanosomes, Leishmania) and nosocomial and neuro-pathogenic fungi (Candida albicans, Cryptococcus neoformans). We use a multi-disciplinary approach of biochemistry, proteomics, molecular pharmacology and genetics to investigate the structure-function relationship, substrate/drug selectivity, protein-protein interaction, and significance for microbial pathogenicity of these membrane proteins at the molecular level in both in vitro culture and animal models. The objective of this project is to use membrane permeases, such as the myo-inositol transporter MIT, for delivery of cytotoxic and parasite-specific substrate analogues as novel pharmacological targets in these microbial pathogens. A second project investigates cytochrome b5 reductase as enzymatic drug target in these opportunistic pathogens. Cytochrome b5 reductase (Cb5r) plays an important role in P450-mediated detoxification of xenobiotics and drugs, lipid biosynthesis, and the synthesis of cholesterol (humans, Leishmania) or ergosterol (fungi and Trypanosoma cruzi). Hence we use recombinant Cb5r protein for biochemical, structural and pharmacological studies and in silico modeling as a novel pharmacological target in these opportunistic microbial pathogens. TECHNIQUES that are applied in the laboratory include protein biochemistry and proteomics, microarray and real-time PCR gene expression analysis, site-directed mutagenesis, targeted gene disruption and reverse genetics, heterologeous expression in Xenopus oocytes microinjected with transporter RNA, and the generation of transgenic protozoa and candida cells. Furthermore, we use axenic cultivation of both mammalian and insect forms of trypanosomes and Leishmania, and candida (yeast and hyphae forms) to probe the pharmacology of these important permeases in vivo. Hence, our studies are aimed to develop novel inositol-based drugs such as fluoro-inositol analogues specific for these microbial pathogens.

 
Links
Personal Page:   https://www.LinkedIn.com/pub/andreas-seyfang/1b/964/bb1
Lab Link:  https://www.ResearchGate.net/profile/Andreas_Seyfang


Selected Publications

Positions Held

Memberships
  • American Society for Microbiology (Member, 2008 - Present)
  • American Association for the Advancement of Science (Member, 2008 - Present)
  • Society for Neuroscience (Member, 2008 - Present)
  • American Society for Biochemistry and Molecular Biology (Member, 2008 - Present)


Awards/Honors
  • Robert J. Grasso Award for Outstanding Dedication to Graduate Education (USF College of Medicine - 2009)
  • AHA Fellowship (American Heart Association - 1997)
  • Alexander von Humboldt Fellow (Alexander von Humboldt Foundation - 1995)
  • FRM Fellowship (Fondation pour la Recherche Médicale (France) - 1994)
  • PhD, Biochemistry with Magna cum laude (University of Tübingen - 1993)
  • EMBO Fellowship (European Molecular Biology Organization - 1993)
  • DAAD Fellowship (German Academic Exchange Service - 1984)


Patents & Licensing
  • Inhibitors Against NAD(P)H Oxidase and ROS Production Protect Against Cytotoxicity of Pathog. Amebae (Andreas Seyfang, Adarsh Bellur, DeAndre Wells & Matthew Doenges: US Patent Application 61/940,683 - 2014)
  • Method for Multiple-Site Directed Mutagenesis (Andreas Seyfang; US Patent 6,878,531 - 2005)


Lectures
  • "Biochemical and Pharmacological Characterization of Cytochrome b5 Reductase as Novel Therapeutic Target in Candida albicans" FEBS Advanced Lecture Course on Human Fungal Pathogens: Molecular Mechanisms of Host-Pathogen Interactions and Virulence, Nice-La Colle sur Loup. France - 2011.
  • "Opportunistic Microbial Pathogens: Chagas Disease and Leishmaniasis as Risk Factors in Blood Transfusion" Hillsborough Community College, Tampa. FL, United States - 2010.
  • "Trypanosoma brucei myo-Inositol Transporter TcMIT: Drug Delivery and Novel Therapeutic Target" International Symposium on the Centennial of the Discovery of Chagas Disease, Rio de Janeiro. Brazil - 2009.
  • "Chagas Disease and Leishmaniasis as Risk Factors in Blood Transfusion" Claro Scientific, Inc. and Florida Blood Services, St. Petersburg. FL, United States - 2009.
  • "Leishmania myo-Inositol Transporter MIT: Drug Delivery and Novel Therapeutic Target." NIH/NIAID and Institut Pasteur de Tunis Conference: “Leishmania – Collaborative Research Opportunities in North Africa and the Middle East”, Tunis. Tunisia - 2009.
  • "Protozoan Parasites as Risk Factors in Transplantation: Chagas’ Disease, Leishmaniasis, and Toxoplasmosis." LifeLink® HealthCare Institute, Tampa. FL, United States - 2008.
  • "Post-Transcriptional Regulation of the Leishmania myo-Inositol Transporter by Substrate Depletion" 23rd Meeting of The German Society for Parasitology, Hamburg. Germany - 2008.
  • "Structure-Function Analysis and Regulation of Leishmania myo-Inositol Transporter MIT" 2nd Annual Molecular Medicine Research Symposium, Tampa. FL, United States - 2007.
  • "Calmodulin-dependent Regulation of myo-Inositol Transport in the Protozoan Leishmania donovani" 22nd Meeting of The German Society for Parasitology, Vienna. Austria - 2006.
  • "Pharmacological Significance of Inositol Metabolism: From Microbial Pathogens to the Human Brain" 1st Annual Molecular Medicine Research Symposium, Tampa,. FL, United States - 2006.
  • "Myocarditis- Infections of the Heart" American Heart Association, Florida/Puerto Rico Affiliate Headquarters, St. Petersburg. FL, United States - 2005.
  • "A Story of Candida albicans and his other Sugar-Coated Buddy, Cryptococcus neoformans" Microbiology and Biodefense Conference, Medical College of Georgia. GA, United States - 2004.
  • "Multiple Site-Directed Mutagenesis of More Than 10 Sites Simultaneously" Georgia Life Sciences Summit 2004, Atlanta. GA, United States - 2004.
  • "Calmodulin-dependent Regulation of myo-Inositol Transport in the Protozoan Leishmania donovani" PharmaConference “Transporters and Drugs”, Pontresina/St.Moritz,. Switzerland - 2003.
  • "Substrate Recognition and Pharmacology of myo-Inositol Transport in Trypanosoma cruzi" PharmaConference: “Membrane Transporters: From Identification to Drug Delivery”, Interlaken. Switzerland - 2001.

Profile last modified on 01/15/2016